Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum's Climate Target Data Preview
As of 2024, Swedish Orphan Biovitrum has disclosed 2 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 2 absolute reduction targets, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into Swedish Orphan Biovitrum ’s climate strategy, ambition level, and alignment with global decarbonization goals.
| Target Type | Scope of Target | Unit | Target | Target Year |
|---|---|---|---|---|
Absolute-based Target | Scope 1 - Total, Scope 2 - Total | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  | 2029 |
Absolute-based Target | Scope 1 - Total, Scope 2 - Total | Metric Tonnes of CO2 equivalent (mtCO2e) | Copy restricted. Please purchase to unlock this data.  | 2030 |
This table provides a simplified preview of selected climate targets data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Swedish Orphan Biovitrum's Greenhouse Gas Emissions Pathways
As of 2024, Swedish Orphan Biovitrum has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions.
Does Swedish Orphan Biovitrum have a target to reduce the emissions from its operations?
As of 2024, Swedish Orphan Biovitrum has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources.
Swedish Orphan Biovitrum's most ambitious operational target is to reduce these emissions by 44.11% by 2030, compared to a baseline of 1,868 Metric Tonnes of CO2 equivalent (mtCO2e) in 2023.
Instead of reducing operational emissions, Swedish Orphan Biovitrum has increased them, with 2024 levels exceeding those of the 2023 baseline, placing the company well behind its reduction target.